10-KPeriod: FY2004

INTUITIVE SURGICAL INC Annual Report, Year Ended Dec 31, 2004

Filed March 16, 2005For Securities:ISRG

Summary

Intuitive Surgical Inc. (ISRG) reported significant year-over-year revenue growth for the fiscal year ending December 31, 2004, with sales reaching $138.8 million, a 51% increase from the previous year. The company achieved its first profitable year, reporting a net income of $23.5 million, or $0.67 per diluted share, a marked improvement from the net loss of $9.6 million in 2003. This financial turnaround was driven by increased adoption of the da Vinci Surgical System, particularly in urologic procedures, and substantial growth in recurring revenue from instruments and services, which now constitute 43% of total sales. The company shipped 76 da Vinci Surgical Systems in 2004, a 25% increase over 2003. The gross margin also improved significantly to 63.4% in 2004 from 48.0% in 2003, reflecting manufacturing efficiencies and cost reductions. Operating expenses grew at a slower pace than revenue, indicating operational leverage. Key strategic achievements in 2004 included FDA clearance for coronary anastomosis procedures and the launch of new 5mm instruments, expanding the system's clinical capabilities.

Key Highlights

  • 1Revenue grew 51% to $138.8 million in 2004.
  • 2Achieved first profitable year with a net income of $23.5 million.
  • 3Gross margin improved significantly to 63.4% in 2004.
  • 4Shipped 76 da Vinci Surgical Systems, a 25% increase year-over-year.
  • 5Recurring revenue (instruments, accessories, service, training) grew over 100% to $60 million, representing 43% of total sales.
  • 6Received FDA clearance for coronary anastomosis procedures.
  • 7Launched new 5mm instrument line, expanding surgical options.

Frequently Asked Questions

Intuitive Surgical designs, manufactures, and markets the da Vinci Surgical System, an advanced robotic surgical system that enables surgeons to perform minimally invasive procedures with enhanced control, precision, and visualization compared to traditional open surgery or standard minimally invasive surgery techniques.

For the fiscal year ending December 31, 2004, Intuitive Surgical reported total sales of $138.8 million, a 51% increase from the prior year. The company achieved profitability for the first time, with a net income of $23.5 million, or $0.67 per diluted share. The gross margin improved significantly to 63.4%.

Revenue growth is driven by increased sales of the da Vinci Surgical System units, higher utilization of installed systems leading to increased sales of instruments and accessories, and recurring revenue from service contracts. The company's focus on key surgical specialties like urology, cardiothoracic, and general surgery, along with expanding its installed base and developing new clinical applications, also contribute significantly to revenue growth.

Key risks include the nascent nature of the robotic surgery market and the need for market acceptance by physicians, hospitals, and payors; long and variable sales cycles for capital equipment; reliance on a few large customers; competition from established surgical techniques and other emerging technologies; manufacturing complexities and potential disruptions; intellectual property protection and litigation; and navigating complex and evolving regulatory environments in the US and internationally.